Announcement
06 Nov 2025
In November 2025, the United States government announced an agreement with Eli Lilly to implement most-favoured-nation drug pricing for American patients. The agreement secured an exemption for Eli Lilly from prospective tariffs on the pharmaceutical imports.
Source
Sign in to access
Number of interventions
3
3 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
31 Jul 2026
Revocation date:
20 Jan 2029
Updated: 07 Nov 2025
Local operations incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 07 Nov 2025
Tax or social insurance relief
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Updated: 07 Nov 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.